The Readout Loud

Episodes

• 419: Assessing Merck and Moderna's mRNA cancer vaccine

  Oct 30, 2026

  Merck and Moderna’s personalized mRNA cancer vaccine Intismeran, combined with Keytruda after melanoma surgery, reduced the risk of disease progression by 42% versus Keytruda alone in the first phase 3 demonstration of strong efficacy for a personalized cancer vaccine.

• 418: Remembering STAT’s Helen Branswell

  Oct 23, 2026

  Not summarized yet

• 417: Hospitals' next lucrative bet — longevity clinics

  Oct 16, 2026

  Not summarized yet

• 416: NIH funding uncertainty thwarts U.S. researchers

  Oct 8, 2026

  Not summarized yet

• 415: Mistrust in science and a juicy gene-editing lawsuit

  Oct 1, 2026

  Not summarized yet

• The FDA's Overton era, and dispatches from Shanghai

  Sep 24, 2026

  Not summarized yet

• Definium's new psychedelics data, and a reprieve for international scientists

  Sep 17, 2026

  Not summarized yet

• Why two promising heart drugs flopped and what's next

  Sep 10, 2026

  Not summarized yet

• 411: Capricor's data clash and a fugitive in the C-suite

  Jul 30, 2026

  Not summarized yet

• 410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

  Jul 23, 2026

  Not summarized yet

• 409: Predicting biotech clinical trials & a new Alzheimer's drug controversy

  Jul 16, 2026

  Not summarized yet

• 408: Whistleblower takes on health insurance and FDA commissioner candidates

  Jul 9, 2026

  Not summarized yet

• 407: The mysterious case of Eli Lilly's obesity drug

  Jun 25, 2026

  Not summarized yet

• 406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

  Jun 18, 2026

  Not summarized yet

• 405: An obesity drug deep-dive, and peptides move mainstream

  Jun 11, 2026

  Not summarized yet

• 404: What RevMed's pancreatic cancer drug meant for one patient

  Jun 4, 2026

  Not summarized yet

• 403: Biotech exec Jeremy Levin on the industry's strategic turning point

  May 28, 2026

  Not summarized yet

• 402: Guarding biotech from China and big bets in longevity

  May 21, 2026

  Not summarized yet

• 401: Makary’s departure and Cassidy’s tenuous Senate seat

  May 14, 2026

  Not summarized yet

• 400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

  May 7, 2026

  Not summarized yet